Nebula Research & Development LLC Purchases New Position in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Nebula Research & Development LLC bought a new stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 9,556 shares of the company's stock, valued at approximately $440,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Barclays PLC lifted its stake in shares of Establishment Labs by 9,643.3% during the 3rd quarter. Barclays PLC now owns 31,471 shares of the company's stock worth $1,362,000 after purchasing an additional 31,148 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Establishment Labs in the fourth quarter worth about $12,898,000. Raymond James Financial Inc. bought a new stake in shares of Establishment Labs in the 4th quarter valued at about $5,494,000. Swiss National Bank boosted its position in shares of Establishment Labs by 2.7% in the 4th quarter. Swiss National Bank now owns 38,500 shares of the company's stock worth $1,774,000 after purchasing an additional 1,000 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Establishment Labs during the 4th quarter worth $161,000. Institutional investors own 72.91% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on ESTA shares. Stephens reiterated an "overweight" rating and issued a $52.00 price target on shares of Establishment Labs in a research note on Thursday, March 6th. Needham & Company LLC assumed coverage on shares of Establishment Labs in a research report on Monday, April 14th. They issued a "hold" rating for the company. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $57.40.

Establishment Labs Stock Performance

Shares of NASDAQ:ESTA traded down $0.37 during trading on Monday, hitting $33.02. The stock had a trading volume of 171,574 shares, compared to its average volume of 460,721. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. Establishment Labs Holdings Inc. has a 12-month low of $26.56 and a 12-month high of $60.12. The stock has a market capitalization of $952.49 million, a price-to-earnings ratio of -12.80 and a beta of 0.73. The stock has a 50-day simple moving average of $35.67 and a two-hundred day simple moving average of $38.83.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.34). The business had revenue of $44.51 million for the quarter, compared to analysts' expectations of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. On average, equities research analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.